compare glp-1 drugs Drug Comparison in Diabetes and Obesity Treatment GLP-1s for Weight Loss: What

10.3389/fncel.2016.00214 Front Cell Neurosci

The clinical evidence establishes unprecedented therapeutic efficacy across established indications, with newer multi-receptor agonists achieving HbA1c reductions exceeding 2.0% in diabetes, weight loss approaching 24% in obesity that rivals bariatric surgery outcomes, and cardiovascular protection demonstrating consistent 1420% MACE reduction with emerging benefits in heart failure with preserved ejection fraction

Jensterle M, Rizzo M, Haluzk M, Jane A

Older adults may be more sensitive to appetite suppression and weight loss, requiring more conservative dosing or closer monitoring

Dighriri, Khalid Hamed, Mohammed N

Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins